Dyne Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DYN Nasdaq 2836 www.dyne-tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dyne Therapeutics, Inc.

Dyne Therapeutics stock rises on positive DM1 trial results - Sep 29th, 2026 3:23 pm
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Sep 29th, 2026 2:05 pm
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 17th, 2026 2:05 pm
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? - Sep 17th, 2026 10:13 am
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Sep 9th, 2026 9:41 am
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Sep 9th, 2026 9:10 am
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls - Sep 9th, 2026 7:51 am
Novartis Stock Tanks Following Third Major Pipeline Setback - Sep 8th, 2026 2:26 pm
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - Sep 8th, 2026 9:04 am
Why the Dow is being dragged down by a Swiss company’s bad news - Sep 8th, 2026 6:47 am
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Sep 8th, 2026 5:51 am
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Sep 8th, 2026 4:50 am
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting - Sep 3rd, 2026 5:30 am
Dyne Therapeutics to Participate in Upcoming Investor Conferences - Sep 2nd, 2026 5:30 am
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Jul 29th, 2026 2:30 pm
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) - Jul 28th, 2026 5:30 am
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Jul 23rd, 2026 2:05 pm